Abstract
Dear Editor
We would like to share ideas on “How We Treat Metastatic Castration-Sensitive Prostate Cancer”. 1 Recent improvements in the treatment of metastatic castration-sensitive prostate cancer (mCSPC) have sparked heated disputes over the best treatment technique and the need for risk stratification. Because mCSPC is so diverse, clinicians are considering more rigorous triple-agent regimens that combine androgen deprivation therapy with second-generation androgen receptor signaling inhibitors and docetaxel to reduce the risk of overtreatment. This method has been validated through case studies, which have been utilized to correlate clinical trial findings. However, one possible shortcoming of this strategy is its reliance on retrospective case reports, which may not provide a complete picture of the broader patient population and may introduce biases that affect treatment recommendations.
Furthermore, enhanced PET imaging has improved the detection of low-volume mCSPC, particularly in patients with lymph node metastases who do not match classic RECIST criteria, a separate category that must be carefully considered in terms of treatment choices. The PSA-adapted method mentioned in the paper seeks to personalize treatment to these patients, however the lack of specialized phase III clinical trials targeting this population makes validating this approach difficult. Future research should prioritize rigorous studies to investigate treatment methods for low-volume mCSPC patients, to guarantee that the findings are generalizable and relevant.
Ongoing clinical trials investigating de-escalation strategies show a shift toward therapy de-escalation, which may lead to overtreatment, especially in patients with a low illness burden. However, it is critical to strike a delicate balance between safely de-escalating treatment and providing the greatest potential outcomes for patients. Future research should focus on identifying validated biomarkers for patient categorization in order to adapt treatment plans more effectively. Furthermore, investigating the impact of socioeconomic factors on treatment access and adherence may give a more equitable approach to mCSPC management.
Local treatments, including those directed at metastases, are promising options for improving outcomes for CSPC patients with oligo-metastases. Patients could benefit greatly from effectively utilizing these tactics in managing mCSPC. However, more uniform guidelines and well-designed clinical trials are required to investigate the successful integration of such medicines. The combined evaluation of combination medicines and local interventions may help to develop novel and improved management approaches for mCSPC, ultimately leading to better care and outcomes.
